A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included DNLI, AQST, RHT, PGRE, and GRA.
Filing 2018 Q3 compared to 2018 Q2 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
John S. Cochran
Vice President
Fort Worth, Texas
14 Nov 2018
The number of shares in Denali Therapeutics Inc. reflected herein includes 1,111,799 shares held by Neuro Line Partners, L.P. over which Bratton Capital Management, L.P. ("Bratton Management") and Bratton Capital, Inc. ("Bratton Capital") have investment discretion. The 11,503,294 shares in Aquestive Therapeutics Inc. reported herein are held by a number of investment entities over which Bratton Management or Bratton Capital have investment discretion. Mr. Bratton has ultimate investment discretion over Bratton Capital Management, L.P., Bratton Capital, Inc. and Crestline Management, L.P.
List of Other Managers Reporting for Crestline Management, LP:
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.